Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
复制标题
DOI：
10.1136/gutjnl-2011-301708
复制
发表时间：
2013-04-01
期刊：
影响因子：
24.5
通讯作者：
Wu, Chun-Ying
中科院分区：
文献类型：
--
作者：
Chen, Hsiao-Ping;Shieh, Jeng-Jer;Wu, Chun-Ying
目的2型糖尿病与肝细胞癌（HCC）的发病风险相关，二甲双胍可降低HCC的发病风险。然而，没有研究二甲双胍对肝癌细胞的影响，从antitumoural perspective.Design在全国范围内的病例对照研究，作者招募了97 430 HCC患者和194 860年龄，性别和医生访问日期匹配的对照。二甲双胍的化学预防作用采用多因素分析和分层分析。结果肝癌患者合并糖尿病的OR值为2.29（95%CI 2.25 ~ 2.35，P < 0.01），合并糖尿病的OR值为2.29（95%CI 2.35 ~ 2.35
Objective Type 2 diabetes mellitus is associated with a higher risk of hepatocellular carcinoma (HCC), which is attenuated by the use of metformin. However, there are no studies addressing the effect of metformin on hepatocarcinoma cells from the antitumoural perspective.Design In the nationwide case-control study, the authors recruited 97 430 HCC patients and 194 860 age-, gender- and physician visit date-matched controls. The chemopreventive effects of metformin were examined by multivariate analysis and stratified analysis. The in vitro effects of metformin on cell proliferation and cell cycle were studied in HepG2 and Hep3B hepatoma cell lines.Results The OR of diabetes in HCC patients was 2.29 (95% CI 2.25 to 2.35, p